Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynectics Regulatory News (SNX)

Share Price Information for Synectics (SNX)

Share Price is delayed by 15 minutes
Get Live Data
200.00    0.00 (0.00%)
Bid:
195.00
Ask:
205.00
Spread: 10.00 (5.128%)
Market Cap: £34.01m
SNX Live PriceLast checked at - London Stock Exchange

Intraday Synectics Share Chart

Offer Document Posted

7 Nov 2007 16:38

Sigma Acquisitions Limited07 November 2007 Not for release, publication or distribution in whole or in part in, into orfrom the United States, Canada, Australia or Japan or any other jurisdictionwhere to do so would constitute a violation of the relevant laws or regulationsof such jurisdiction. Recommended Cash Offer by Deloitte Corporate Finance on behalf of SigmaAcquisitions Limited ("Sigma Acquisitions") for Synexus Clinical Research plc ("Synexus") Posting of Offer Document Further to the announcement made earlier today of a recommended cash offer bySigma Acquisitions to acquire the entire issued and to be issued share capitalof Synexus (other than Synexus Shares already contracted to be acquired by SigmaAcquisitions)(the "Offer"), Sigma Acquisitions announces that the offer documentcontaining the full terms and conditions of the Offer (the "Offer Document") hastoday been posted to Synexus Shareholders, together with the Form of Acceptanceand Form of Proxy. If you hold Synexus Shares in certificated form (that is, not in CREST), toaccept the Offer you should complete, sign and return the Form of Acceptance inaccordance with the instructions set out in the Offer Document and on the Formof Acceptance as soon as possible and, in any event, so as to be received byCapita Registrars by no later than 3.00 p.m. on 28 November 2007. If you hold Synexus Shares in uncertificated form (that is, in CREST), to acceptthe Offer, you should do so electronically through CREST in accordance with theinstructions set out in the Offer Document so that the TTE Instruction settlesby no later than 3.00 p.m. on 28 November 2007. If you hold Synexus Shares as aCREST sponsored member, you should refer to your CREST sponsor as only yourCREST sponsor will be able to send the necessary TTE Instruction to Euroclear inrelation to your Synexus Shares. Copies of the Offer Document and Form of Acceptance will be available forinspection at the offices of Travers Smith, 10 Snow Hill, London EC1A 2AL duringnormal business hours on any weekday (Saturdays and public holidays excluded)while the Offer remains open for acceptance. Additional Forms of Acceptance areavailable from Capita Registrars, Corporate Actions, The Registry, 34 BeckenhamRoad, Beckenham, Kent BR3 4TU. Terms defined in the Offer Document have the same meanings in this announcement. EnquiriesSigma Acquisitions/Lyceum Capital 020 7632 2480Jeremy HandGrant DavidsonDeloitte Corporate Finance (financial adviser to Sigma Acquisitions) 020 7936 3000Jonathan HintonJames LewisPR advisers to Lyceum CapitalChantal Ligertwood 01235 834 091Sally Brown 020 8871 0536 This announcement does not constitute an offer or invitation to purchase anysecurities, nor is it a solicitation of any vote or approval in anyjurisdiction, nor shall there be any sale, issuance or transfer of thesecurities referred to in this announcement in any jurisdiction in contraventionof applicable law or regulation. The Offer will be made solely by means of theOffer Document and (in the case of Synexus Shares in certificated form) the Formof Acceptance accompanying the Offer Document, which contains the full terms andconditions of the Offer including details of how it may be accepted and by wayof notice to be published in the London Gazette on 9 November 2007. Deloitte Corporate Finance is acting for Sigma Acquisitions and Lyceum CapitalPartners LLP and for no-one else in connection with the Offer and will notregard any other person as its client nor be responsible to anyone other thanSigma Acquisitions and Lyceum Capital Partners LLP for providing the protectionsafforded to clients of Deloitte Corporate Finance nor for providing advice inrelation to the Offer or any matter referred to in this announcement. DeloitteCorporate Finance is a division of Deloitte & Touche LLP, which is authorisedand regulated by the Financial Services Authority in respect of regulatedactivities. This announcement has been prepared for the purpose of complying with Englishlaw and the City Code and the information disclosed may not be the same as thatwhich would have been disclosed if this announcement had been prepared inaccordance with the laws and/or regulations of jurisdictions outside the UK. The availability of the Offer to Synexus Shareholders who are not resident inthe United Kingdom may be affected by the laws or regulations of the relevantjurisdictions in which they are located. Persons who are not resident in theUnited Kingdom should inform themselves about, and observe, applicable legal orregulatory requirements of their jurisdiction. The Offer will not be made, directly or indirectly, in or into, or by use of themails, or by any means or instrumentality (including, without limitation, telex,facsimile transmission, telephone, internet or other forms of electroniccommunication) of interstate or foreign commerce of, or by any facilities of anational securities exchange of, the United States, Canada, Australia or Japanor any other jurisdiction if to do so would constitute a violation of therelevant laws or regulations of such jurisdiction and the Offer cannot beaccepted by any such use, means or instrumentality or otherwise from or withinthe United States, Canada, Australia or Japan or any other jurisdiction if to doso would constitute a violation of the relevant laws or regulations of suchjurisdiction. Accordingly, copies of this announcement are not being, and mustnot be, mailed or otherwise forwarded, distributed or sent in or into or fromany such jurisdiction. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Mar 20077:00 amRNSHolding(s) in Company
20th Feb 200712:33 pmRNSGrant of Options
7th Feb 20077:02 amRNSNorth American Contract Wins
7th Feb 20077:02 amRNSInterim Results
6th Feb 200710:14 amRNSDirector/PDMR Shareholding
5th Feb 20077:00 amRNSDirectorate Change
29th Jan 20072:58 pmRNSNotice of Results
26th Jan 20077:01 amRNSTrading Update
28th Dec 20064:36 pmRNSGrant of Options
22nd Dec 20069:37 amRNSTotal Voting Rights & Capital
5th Dec 20067:01 amRNSInterim Results
29th Nov 20063:25 pmRNSDirector/PDMR Shareholding
24th Nov 200611:53 amRNSNotice of Results
24th Oct 20067:01 amRNSAcquisition
4th Oct 20067:00 amRNSTrading Statement
18th Sep 20069:11 amRNSDirectorate Change
13th Jul 20067:01 amRNSIssue of Equity
20th Jun 200610:39 amRNSGrant of Options
14th Jun 20065:06 pmRNSIssue of Equity
6th Jun 20067:03 amRNSFinal Results
6th Jun 20067:02 amRNSAcquisition of DUH
6th Jun 20067:02 amRNSDirectorate Change
9th May 20062:31 pmRNSIssue of Equity
21st Apr 20062:15 pmRNSHolding(s) in Company
21st Apr 20067:00 amRNSContract Win
11th Apr 200612:19 pmRNSIssue of Equity
10th Apr 20067:01 amRNSPre-Close Statement
6th Apr 200612:39 pmRNSHolding(s) in Company
30th Mar 20062:30 pmRNSHolding(s) in Company
29th Mar 20063:28 pmRNSHolding(s) in Company
24th Mar 20065:39 pmRNSIssue of Equity
22nd Mar 20065:03 pmRNSDirector/PDMR Shareholding
21st Mar 20064:34 pmRNSIssue of Equity
14th Mar 200610:23 amRNSIssue of Equity
6th Mar 20066:00 pmRNSIssue of Equity
6th Mar 20064:01 pmRNSHolding(s) in Company
28th Feb 20061:34 pmRNSHolding(s) in Company
24th Feb 20064:51 pmRNSHolding(s) in Company
23rd Feb 20065:57 pmRNSIssue of Equity
22nd Feb 20064:21 pmRNSHolding(s) in Company
6th Feb 200610:38 amRNSIssue of Equity
31st Jan 20068:00 amRNSAcquisition
27th Jan 20064:48 pmRNSIssue of Equity
27th Jan 20064:45 pmRNSOffer Update
13th Jan 20065:02 pmRNSIssue of Equity
9th Jan 200612:14 pmRNSIssue of Equity
3rd Jan 20065:28 pmRNSIssue of Equity
20th Dec 20054:32 pmRNSHolding(s) in Company
20th Dec 200512:53 pmRNSDirector/PDMR Shareholding
20th Dec 200512:41 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.